# The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar

> **NCT04132479** · PHASE4 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 313 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Clarithromycin 500mg
- **DRUG:** Amoxicillin 500mg
- **DRUG:** Tinidazole 500mg
- **DRUG:** Rabeprazole 20mg
- **DRUG:** Clarithromycin 500mg
- **DRUG:** Amoxicillin 500mg
- **DRUG:** Tinidazole 500mg
- **DRUG:** Rabeprazole 20mg

## Key facts

- **NCT ID:** NCT04132479
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-04-09
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2019-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04132479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04132479, "The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04132479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*